Novocure Limited · NASDAQ:NVCR
Novocure — Q3 2025 Earnings Presentation
11 slides from Novocure's earnings presentation, Oct 30, 2025
Slide 1: Novocure Q3 2025 earnings
Novocure Q3 2025 earnings Thursday, October 30, 2025 Confidential © 2024 Novocu © 2025 re GmbH Novocu re GmbH 1
Slide 2: Forward-looking statements
forward - looking statements In addition to historical facts or statements of current condition, this presentation may contain forward - looking statements. Fo rward - looking statements provide Novocure’s current expectations or forecasts of future events. These may include statements regarding ant
Slide 3: 2025 key objectives, unlocking TTFields potential
2025 key objectives, unlocking TTFields potential DRIVING COMMERCIAL ADVANCING DELIVERING ADOPTION CLINICAL PIPELINE PRODUCT INNOVATION ✓ NSCLC drive global active ✓PANOVA - 3 data presented ✓Launch MyNovocure patient growth and pursue and published patient app reimbursement ✓PANOVA - 3 marketing ✓N
Slide 4: Q3 financial and operational updates
q3 financial and operational updates Consistent commercial, clinical and regulatory execution • Quarterly net revenues of $167 million , +8% year - over - year • Record 4,416 active patients on therapy, +7% year - over - year (GBM +5% year - over - year) • 109 NSCLC prescriptions received, 100 NSCLC
Slide 5: Q3 NSCLC launch results by the numbers
q3 NSCLC launch results by the numbers GLOBAL NSCLC PRESCRIPTIONS RECEIVED PHYSICIAN PROFILE PATIENT PROFILE THERAPY TIMING PRESCRIBER BREADTH CONCOMITANT THERAPY QUICK STARTS 109 84 unique prescribers 59% / 41% split between concomitant 23 - day average time between prescription ICI or docetaxel an
Slide 6: Positive outcomes across multiple solid tumor indications
positive outcomes across multiple solid tumor indications non - small cell brain mets locally advanced glioblastoma lung cancer from NSCLC pancreatic cancer 1.0 HR = 0.63 HR = 0.74 HR = 0.72 HR = 0.82 P- value < 0.001 P- value = 0.035 0.8 P- value = 0.044 P- value = 0.039 Probability of intracranial
Slide 7: Q3 2025 select financials
q3 2025 select financials U.S. DOLLARS IN MILLIONS Q3 2025 Q3 2024 Net revenues $ 167.2 $ 155.1 Cost of revenues 44.7 35.4 Gross profit 122.5 119.7 Research, development and clinical expenses 54.0 51.9 Sales and marketing 58.5 59.8 General and administrative 45.9 40.1 Total operating costs and expen
Slide 8: Together with our patients, we strive to extend survival in some of the most aggressive forms of cancer
together with our patients, we strive to extend survival in some of the most aggressive forms of cancer Confidential © 2024 Novocu © 2025 re GmbH Novocu re GmbH 8
Slide 9: Adjusted EBITDA reconciliation
adjusted EBITDA reconciliation Adjusted EBITDA is a non - GAAP measurement of earnings before interest, taxes, depreciation, amortization and share - based compens ation. We believe Adjusted EBITDA is useful to investors in evaluating our operating performance because it helps investors compare the
Slide 10: Optune Lua and Optune Gio indications for use and important safety information
Optune Lua ® and Optune Gio ® indications for use and important safety information INDICATIONS • Optune Lua ® is indicated as a treatment concurrent with PD - 1/PD - L1 inhibitors or docetaxel for adult patients with metastatic non - small cell lung cancer ( mNSCLC ) who have progressed on or after
Slide 11: Optune Lua and Optune Gio indications for use and important safety information
Optune Lua ® and Optune Gio ® indications for use and important safety information WARNINGS AND PRECAUTIONS • Optune Lua and Optune Gio can only be prescribed by a healthcare provider that has completed the required certification training provided by Novocu re ® (the device manufacturer). • Do not p